187 related articles for article (PubMed ID: 33372813)
1. Exploring the role of the complement system, endothelial injury, and microRNAs in thrombotic microangiopathy after kidney transplantation.
Aleš Rigler A; Večerić-Haler Ž; Arnol M; Perše M; Boštjančič E; Pleško J; Simčič S; Kojc N
J Int Med Res; 2020 Dec; 48(12):300060520980530. PubMed ID: 33372813
[TBL] [Abstract][Full Text] [Related]
2. De novo thrombotic microangiopathy after kidney transplantation.
Garg N; Rennke HG; Pavlakis M; Zandi-Nejad K
Transplant Rev (Orlando); 2018 Jan; 32(1):58-68. PubMed ID: 29157988
[TBL] [Abstract][Full Text] [Related]
3. Clinical profile and outcomes of
Saikumar Doradla LP; Lal H; Kaul A; Bhaduaria D; Jain M; Prasad N; Thammishetti V; Gupta A; Patel M; Sharma RK
Saudi J Kidney Dis Transpl; 2020; 31(1):160-168. PubMed ID: 32129209
[TBL] [Abstract][Full Text] [Related]
4. De novo thrombotic microangiopathy in two kidney transplant recipients from the same deceased donor: A case series.
Roberts D; Siegman I; Andeen N; Woodland D; Deloughery T; Rueda J; Olyaei A; Rehman S; Norman D; Lockridge J
Clin Transplant; 2020 Jul; 34(7):e13885. PubMed ID: 32314417
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the prevalence of systemic de novo thrombotic microangiopathy after ABO-incompatible kidney transplantation and the associated risk factors.
Tasaki M; Saito K; Nakagawa Y; Imai N; Ito Y; Yoshida Y; Ikeda M; Ishikawa S; Narita I; Takahashi K; Tomita Y
Int J Urol; 2019 Dec; 26(12):1128-1137. PubMed ID: 31587389
[TBL] [Abstract][Full Text] [Related]
6.
Petr V; Csuka D; Hruba P; Szilágyi Á; Kollar M; Slavcev A; Prohászka Z; Viklicky O
Front Immunol; 2022; 13():985766. PubMed ID: 36189289
[No Abstract] [Full Text] [Related]
7. De novo thrombotic microangiopathy induced by cytomegalovirus infection leading to renal allograft loss.
De Keyzer K; Van Laecke S; Peeters P; Vanholder R
Am J Nephrol; 2010; 32(5):491-6. PubMed ID: 20975262
[TBL] [Abstract][Full Text] [Related]
8. De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival.
Caires RA; Marques ID; Repizo LP; Sato VA; Carmo LP; Machado DJ; de Paula FJ; Nahas WC; David-Neto E
Transplant Proc; 2012 Oct; 44(8):2388-90. PubMed ID: 23026601
[TBL] [Abstract][Full Text] [Related]
9. Unveiling the Incidence and Graft Survival Rate in Kidney Transplant Recipients With
Hsiung CY; Chen HY; Wang SH; Huang CY
Transpl Int; 2024; 37():12168. PubMed ID: 38323071
[No Abstract] [Full Text] [Related]
10. Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report.
Chandran S; Baxter-Lowe L; Olson JL; Tomlanovich SJ; Webber A
Transplant Proc; 2011 Jun; 43(5):2097-101. PubMed ID: 21693335
[TBL] [Abstract][Full Text] [Related]
11. An analysis of transplant glomerulopathy and thrombotic microangiopathy in kidney transplant biopsies.
Sreedharanunni S; Joshi K; Duggal R; Nada R; Minz M; Sakhuja V
Transpl Int; 2014 Aug; 27(8):784-92. PubMed ID: 24684170
[TBL] [Abstract][Full Text] [Related]
12. De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab.
Shochet L; Kanellis J; Simpson I; Ta J; Mulley W
Nephrology (Carlton); 2017 Feb; 22 Suppl 1():23-27. PubMed ID: 28176480
[TBL] [Abstract][Full Text] [Related]
13. De novo thrombotic microangiopathy. An underrated complication of renal transplantation.
Ponticelli C
Clin Nephrol; 2007 Jun; 67(6):335-40. PubMed ID: 17598367
[TBL] [Abstract][Full Text] [Related]
14. Immunological risk and complement genetic evaluations in early onset de novo thrombotic microangiopathy after living donor kidney transplantation: A Japanese multicenter registry.
Fujiyama N; Tasaki M; Harada H; Tsutahara K; Matsumoto A; Kamijo Y; Toyoda M; Iwami D; Inui M; Shirakawa H; Sugimura J; Saito M; Hotta K; Okumi M; Saito K; Watarai Y; Hidaka Y; Ohtani K; Inoue N; Wakamiya N; Habuchi T; Satoh S;
Clin Exp Nephrol; 2023 Dec; 27(12):1010-1020. PubMed ID: 37634218
[TBL] [Abstract][Full Text] [Related]
15. Emerging Concepts in Hematopoietic Stem Cell Transplantation-Associated Renal Thrombotic Microangiopathy and Prospects for New Treatments.
Wanchoo R; Bayer RL; Bassil C; Jhaveri KD
Am J Kidney Dis; 2018 Dec; 72(6):857-865. PubMed ID: 30146419
[TBL] [Abstract][Full Text] [Related]
16. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation.
Nava F; Cappelli G; Mori G; Granito M; Magnoni G; Botta C; Solazzo A; Fontana F; Baisi A; Bonucchi D
Transplant Proc; 2014 Sep; 46(7):2263-8. PubMed ID: 25242766
[TBL] [Abstract][Full Text] [Related]
17. De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus.
Cortina G; Trojer R; Waldegger S; Schneeberger S; Gut N; Hofer J
Pediatr Nephrol; 2015 Apr; 30(4):693-7. PubMed ID: 25577332
[TBL] [Abstract][Full Text] [Related]
18. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy.
Schwimmer J; Nadasdy TA; Spitalnik PF; Kaplan KL; Zand MS
Am J Kidney Dis; 2003 Feb; 41(2):471-9. PubMed ID: 12552512
[TBL] [Abstract][Full Text] [Related]
19. Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities.
Timmermans SAMEG; Abdul-Hamid MA; Vanderlocht J; Damoiseaux JGMC; Reutelingsperger CP; van Paassen P;
Kidney Int; 2017 Jun; 91(6):1420-1425. PubMed ID: 28187980
[TBL] [Abstract][Full Text] [Related]
20. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
